Techniclone Announces Interim Results From TNT Phase I Study.

TUSTIN, Calif.--(BUSINESS WIRE)--Aug. 28, 1998--Techniclone Corporation (NASDAQ:TCLN) a developer of leading-edge unique therapeutics for the advanced treatment of cancer, announced today its interim results from the dosimetry phase in the Phase I Tumor Necrosis Therapy (TNT) clinical trial for treating malignant glioma (brain cancer), which are being conducted at the Medical University of South Carolina (MUSC).

Phase I clinical studies are designed to demonstrate drug safety, rather than measuring response to treatment. Of the six patients assessed for safety, five had magnetic resonance imaging (MRI) data available for more than thirty days after treatment to evaluate tumor response. Although these patients received doses of only one-third to one-half of the newly established dose of 15,000 centigray (cGy), all five patients demonstrated stabilization of their disease (one patient for thirty days, four patients for greater than sixty days). More importantly, in three of the five patients,the primary tumor actually decreased in size. The sixth patient was recently treated and will be evaluated for any response in the normal course of treatment as outlined by the protocol.

"Malignant glioma is a rapidly progressive disease with a median survival of nine-twelve months from diagnosis," stated Dr. Sunil Patel, Assistant Professor of Neurological Surgery at MUSC. "In these patients, being able to stabilize this disease is the best that can be hoped for. To actually see tumors shrink is very exciting. These Phase I results are even more compelling considering these first six patients received approximately one-third to one-half of what we consider to be an effective dose for treatment in this disease."

Additional results from the data reveal that the Karnofsky Performance Score (KPS), a well-known barometer of patient well-being, increased or remained stable in sixty-six percent of patients, that there was no observation of hematological (blood) toxicity or clinically significant changes in blood chemistry, and that there was no observation of any infusion related adverse events.

Dr. Jamie Oliver, Vice-President of Clinical and Regulatory Affairs for Techniclone commented, "The initial nuclear imaging scans indicate that the drug does, in fact, migrate throughout tumor tissue. There was also no sign of drug distribution outside of the observable tumor."

Larry O. Bymaster, President and Chief Executive Officer of Techniclone stated, "The ongoing efforts of Dr. Patel and the staff at MUSC have made a significant contribution to the speed and high standard of patient care, thereby allowing us to advance more rapidly along in our TNT development process. In addition, we have advanced our timeline by nearly six months ahead of schedule, which allows us to file our Phase II protocol shortly with the FDA. We are very pleased that (as previously announced) MUSC and Dr. Patel will continue as a Phase II clinical trial center."

Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Techniclone's reports on file with the U.S. Securities and Exchange Commission, including but not limited to, the Company's report on Form 10K for the year ended April 30, 1998.

Company Overview: Techniclone Corporation is engaged in the research and development of unique therapeutics for the treatment of cancer. The Company utilizes innovative targeting technologies to develop products capable of destroying cancerous tumors throughout the body. Presently in Phase 1 clinical testing, the Company's Tumor Necrosis Therapy (TNT) is designed to deliver high doses of radiation directly to the core of the tumor while causing minimal damage to surrounding tissue. Oncolym(R), a therapy for the treatment of advanced non-Hodgkin's B-cell Lymphoma, is currently undergoing Phase II/III human testing.

The Company is also developing two additional technologies for the treatment of solid tumors, Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA). VEAs act on tumors to increase the concentration of conventional chemotherapy in the tumor site white VTAs attach to tumor blood vessels creating a blood clot, that kills the tumor by eliminating its oxygen and nutrient supply. Additional information on the Company and its products can be found at www.techniclone.com.

    CONTACT:  Techniclone Corporation, Tustin
               Greg Facktor, 714-508-6100
                             or
               Cynthia DeMonte, New York
               Investor Relations
               212-420-0088
                             or
               Rubenstein PR, New York
               Media Relations
               Clint Cantwell
               212-843-8051